April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Morphological features and determinants of new geographic atrophy developing in participants in the IVAN trial.
Author Affiliations & Notes
  • Frank Picton
    NIHR Biomedical Research Centre, Moorfields Eye Hospital, London, United Kingdom
    Centre for Experimental Medicine, Queens University Belfast, Belfast, United Kingdom
  • Katherine A Muldrew
    Centre for Experimental Medicine, Queens University Belfast, Belfast, United Kingdom
  • Barney Reeves
    School of Clinical Sciences, Bristol University, Bristol, United Kingdom
  • Chris Rogers
    School of Clinical Sciences, Bristol University, Bristol, United Kingdom
  • Simon P Harding
    Eye and Vision Science, University of Liverpool, Liverpool, United Kingdom
  • Usha Chakravarthy
    Centre for Experimental Medicine, Queens University Belfast, Belfast, United Kingdom
  • Tunde Peto
    NIHR Biomedical Research Centre, Moorfields Eye Hospital, London, United Kingdom
  • Footnotes
    Commercial Relationships Frank Picton, None; Katherine Muldrew, None; Barney Reeves, None; Chris Rogers, None; Simon Harding, None; Usha Chakravarthy, None; Tunde Peto, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 4977. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Frank Picton, Katherine A Muldrew, Barney Reeves, Chris Rogers, Simon P Harding, Usha Chakravarthy, Tunde Peto, NetworcUK; Morphological features and determinants of new geographic atrophy developing in participants in the IVAN trial.. Invest. Ophthalmol. Vis. Sci. 2014;55(13):4977.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To describe the ocular features of the geographic atrophy (GA) that developed in participants in the alternative treatments in the Inhibition of VEGF in Age-related choroidal Neovascularisation (IVAN) clinical trial.

 
Methods
 

The IVAN trial enrolled 610 participants who were randomized in a factorial design to either ranibizumab or bevacizumab given either monthly or discontinuously. GA developed during time on study in the study eye (n = 28). When GA existed at baseline, this expanded (n = 1) and new foci developed.(n = 1). The colour and fluorescein angiograms (FA) of these 30 participants were subjected to a secondary grading. The position of GA with respect to the lesion (within, contiguous or remote), its location with respect to macular quadrant, the presence of a PED were recorded and the area of GA measured at month 12 and 24. The fellow eye was assessed at baseline for presence of drusen, type of drusen, GA, and when nAMD was present, an attempt was made to ascertain if it was a retinal angiomatous proliferation (RAP).

 
Results
 

GA had developed by the 12 month visit in 17 participants. The area of GA ranged from 0.1mm2 to 5.14 mm2 and increased in all but two eyes during the two year period. GA was located within the lesion in 42%, contiguous to the lesion in 37% and remote to the lesion in 21%. In 18 of the 30 eyes a PED was recorded at baseline. When GA developed it mainly occurred at the site of the PED (12 of 18; 66%). Examination of the fellow eye showed the predominant drusen type was large soft and found in 40% of participants. In 16% of fellow eyes foci of GA were identified at baseline. Reticular drusen were not identified in any of the fellow eyes. Approximately half of the group had nAMD in the fellow eye. An RPE tear was present in two eyes but the area devoid of RPE was distinct from the area of GA.

 
Conclusions
 

The association of GA with more frequent use of anti VEGF agents was raised by the comparison of age-related macular degeneration treatment trials (CATT) and confirmed by IVAN. However, the strong spatial localisation of GA to the area of pre existing PED suggests a predisposition to atrophy in eyes with this characteristic.

 
Keywords: 550 imaging/image analysis: clinical • 748 vascular endothelial growth factor • 412 age-related macular degeneration  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×